Revvity has introduced a CE-IVD declared platform, EONIS Q, to enable molecular testing in newborns for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA).

By utilising the EONIS Q96 instrument, EONIS SCID-SMA kit, and EONIS EASI software, the system helps simplify and streamline molecular testing for both conditions.

The turnaround time for this workflow, measured from sample intake to providing results, is approximately three hours.

The EONIS Q workflow's compact size and smaller footprint make it suitable for labs of all sizes. It is claimed to benefit small and medium-throughput labs, even those without a PCR cleanroom.

Aside from not needing to be cleaned, the device requires fewer pipetting and centrifuging steps, thereby reducing hands-on time.

The EONIS Q system is claimed to be more resourceful and cost-efficient for labs as it utilises fewer consumables and single-use plastic items compared with alternative methods.

Revvity reproductive health general manager Petra Furu said: “Helping children get a healthier start to life is at the heart of our work and making molecular testing for inherited conditions like SMA and SCID more accessible can help further that aim.

“Without compromising quality, speed or test result accuracy, the EONIS Q system is designed to break down some of the common barriers that prevent newborn screening labs from adopting these tests.”

The European Alliance for Newborn Screening in SMA, a group supported by SMA Europe, requires that all newborns in Europe undergo SMA screening by 2025.

Last month, Revvity and Element Biosciences, a developer of a genomic sequencing platform, announced a collaboration to roll out workflow solutions to save the time and effort needed for the genomic analysis of samples.

In 2022, Revvity generated over $3bn in revenue and employed more than 11,000 people. It caters to customers in the pharmaceutical and biotech industries, as well as the academia and government sectors.